Remestemcel-L is under clinical development by Mesoblast and currently in Phase III for Crohn's Disease (Regional Enteritis).

The chain filed for bankruptcy protection in September, saying inflation and high interest rates caused consumers to pull ...

From drug shortages to the approval of a nasal spray flu vaccine ... predictable out-of-pocket costs for improving medication ...